Skip to content

Keryx beats revenue, misses earnings views

May 4, 2017

Keryx Biopharma (NASDAQ: KERX) reported Q1 EPS of ($0.21), $0.01 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $11.8 million versus the consensus estimate of $10.27 million.

2017 Financial Guidance

Keryx today provided financial guidance for full year 2017 net U.S. Auryxia product sales of $56 to $60 million. The guidance is based on the company’s current understanding of Auryxia prescriptions trends in dialysis. Guidance excludes potential sales from the potential approval in November 2017 of ferric citrate in the U.S. for the treatment of adults with NDD-CKD and iron deficiency anemia.


  • Company reported $11.8 million in first quarter 2017 total revenue, including net U.S. Auryxia® (ferric citrate) product sales of $10.5 million
  • Provides 2017 net U.S. Auryxia product sales guidance of $56 to $60 million
  • Target action date of November 6, 2017 set for supplemental new drug application (sNDA) to expand indication of ferric citrate; Expanded indication would leverage reimbursement access, awareness and existing infrastructure


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: